Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines
Authors not listed
Revance Therapeutics, Inc. · 2015
Abstract
This is a safety and efficacy study of botulinum toxin type A in subjects with lateral canthal lines.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-28 MST
Cite this
APA
Anonymous. (2015). Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines. <em>Revance Therapeutics, Inc.</em>. https://clinicaltrials.gov/study/NCT02580370
Vancouver
Anonymous. Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines. Revance Therapeutics, Inc.. 2015.
BibTeX
@misc{anon2015Safety,
title = {Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines},
author = {Anonymous},
journal = {Revance Therapeutics, Inc.},
year = {2015},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Revance Therapeutics, Inc. 2013
Open access · US-GOV
Efficacy and Safety of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines
Istituto Oncologico Veneto IRCCS 2019
Open access · US-GOV
Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma: Observational Study
AbbVie (prior sponsor, Abbott) 2009
Open access · US-GOV
A Randomized, Double-Blind, Active- and Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease
Galaxia Empírica 2023
Open access · US-GOV
Safety Evaluation of Edoxaban in Elderly Patients With Frailty Criteria
Biolab Sanus Farmaceutica 2009
Open access · US-GOV
Phase III Open Label Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face
Diabetes Care 2016
Preprint · OA